Adicet Bio

Compare

808 Followers

ACET Stock Chart & Stats

$0.75

-$0.04(-4.07%)

At close: Jan 08 4:00 PM EST

$0.75

-$0.04(-4.07%)

Day’s Range― - ―

52-Week Range$0.45 - $1.54

Previous CloseN/A

Volume197.46K

Average Volume (3M)1.92M

Market Cap

$115.02M

Enterprise Value-$54.04M

Total Cash (Recent Filing)$34.72M

Total Debt (Recent Filing)$15.36M

Price to Earnings (P/E)―

Beta1.80

Next Earnings

Nov 05, 2025

EPS Estimate

-0.29

Last Dividend Ex-Date

Sep 21, 2018

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding153,254,780

10 Day Avg. Volume4,877,229

30 Day Avg. Volume1,918,806

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)0.45

Price to Sales (P/S)0.00

P/FCF Ratio-0.90

Enterprise Value/Market Cap-0.47

Enterprise Value/Revenue-8.31

Enterprise Value/Gross Profit33.38

Enterprise Value/Ebitda0.46

Forecast

1Y Price Target

$6.50

Price Target Upside766.67% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Competitive AdvantagePromising outcomes from off-the-shelf cell therapy give Adicet a competitive edge.

Market PotentialApproximately 14% of rheumatoid arthritis patients become treatment-refractory, creating a large unmet need that ADI-001 aims to address.

Product DevelopmentThe inclusion of rheumatoid arthritis adds to the growing list of data readouts, bringing ADI-001's lineup of autoimmune indications up to seven.

Bears Say

Adicet Bio News

Adicet Bio doses first patient in ADI-001 trial

Adicet Bio (ACET) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating...

15d ago

ACET

Adicet Bio price target raised to $8 from $7 at Guggenheim

Guggenheim raised the firm’s price target on Adicet Bio (ACET) to $8 from $7 and keeps a Buy...

23d ago

ACET

Adicet Bio announces $80M registered direct offering

Adicet Bio (ACET) “announced the pricing of an underwritten registered direct offering of 70,001,000 shares of its common...

23d ago

ACET

Adicet Bio’s ADI-001 shows positive preliminary Phase 1 results in LN and SLE

Adicet Bio (ACET) announced initial safety and efficacy data from the first seven patients dosed with ADI-001 in...

24d ago

ACET

Adicet Bio’s Promising Off-the-Shelf Cell Therapy Garners Buy Rating Due to Positive Clinical Outcomes and Strong Market Position

Analyst Soumit Roy from JonesTrading reiterated a Buy rating on Adicet Bio and increased the price target to...

22d ago

ACET

Adicet Bio Receives Nasdaq Extension for Compliance

The latest update is out from Adicet Bio ( ($ACET) ). On October 7, 2025, Adicet Bio received...

23d ago

ACET

Adicet Bio Announces Major Stock Offering Agreement

Adicet Bio ( ($ACET) ) just unveiled an update. On October 7, 2025, Adicet Bio, Inc. entered into...

23d ago

ACET

Adicet Bio Reports Promising Phase 1 Study Results

The latest announcement is out from Adicet Bio ( ($ACET) ). On October 7, 2025, Adicet Bio announced...

23d ago

ACET

Adicet Bio’s Promising CAR γδ T Cell Therapy: A Buy Rating Amidst Anticipated Breakthroughs in Lupus Treatment

Adicet Bio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from...

29d ago

ACET

Adicet Bio’s Promising Developments and Strategic Advancements Justify Buy Rating

Adicet Bio, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst John Newman from...

3M ago

ACET

Adicet Bio: Strategic Advancements and Financial Prudence Drive Buy Rating

JonesTrading analyst Soumit Roy has maintained their bullish stance on ACET stock, giving a Buy rating yesterday. Soumit...

3M ago

ACET

Adicet Bio Reports Q2 2025 Financial Results

Adicet Bio Inc ( ($ACET) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

ACET

Adicet Bio reports Q2 EPS (34c), consensus (30c)

“We continue to make meaningful progress in our ADI-001 autoimmune Phase 1 clinical program. Site activation is progressing...

3M ago

ACET

Promising Pipeline and FDA Fast Track Designations Justify Buy Rating for Adicet Bio

Adicet Bio (ACET) has received a new Buy rating, initiated by H.C. Wainwright analyst, Robert Burns. Robert Burns’s...

3M ago

ACET

ACET FAQ

What was Adicet Bio’s price range in the past 12 months?

Adicet Bio lowest stock price was $0.45 and its highest was $1.54 in the past 12 months.

What is Adicet Bio’s market cap?

Adicet Bio’s market cap is $115.02M.

When is Adicet Bio’s upcoming earnings report date?

Adicet Bio’s upcoming earnings report date is Nov 05, 2025 which is in 6 days.

How were Adicet Bio’s earnings last quarter?

Adicet Bio released its earnings results on Aug 07, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.304 by -$0.036.

Is Adicet Bio overvalued?

According to Wall Street analysts Adicet Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Adicet Bio pay dividends?

Adicet Bio pays a Quarterly dividend of $0.01 which represents an annual dividend yield of N/A. See more information on Adicet Bio dividends here

What is Adicet Bio’s EPS estimate?

Adicet Bio’s EPS estimate is -0.29.

How many shares outstanding does Adicet Bio have?

Adicet Bio has 153,254,780 shares outstanding.

What happened to Adicet Bio’s price movement after its last earnings report?

Adicet Bio reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.304. Following the earnings report the stock price went down -10.145%.

Which hedge fund is a major shareholder of Adicet Bio?

Currently, no hedge funds are holding shares in ACET

Adicet Bio Stock Smart Score

Outperform

Fundamentals

Return on Equity

-64.39%

Trailing 12-Months

Asset Growth

-39.38%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Adicet Bio

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Adicet Bio (ACET) Earnings & Revenues

Historic Earnings Reports

ACET Stock 12 Month Forecast

Average Price Target

$6.50

▲(766.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.82,1.3723076923076922,1.9246153846153846,2.4769230769230766,3.029230769230769,3.5815384615384613,4.133846153846154,4.686153846153846,5.2384615384615385,5.7907692307692304,6.343076923076923,6.895384615384615,7.447692307692307,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.82,1.2569230769230768,1.6938461538461538,2.1307692307692307,2.5676923076923077,3.0046153846153842,3.441538461538461,3.878461538461538,4.315384615384615,4.752307692307692,5.189230769230769,5.626153846153846,6.063076923076923,{"y":6.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.82,1.1415384615384614,1.463076923076923,1.7846153846153845,2.106153846153846,2.4276923076923076,2.7492307692307687,3.0707692307692303,3.392307692307692,3.7138461538461534,4.035384615384615,4.356923076923077,4.678461538461538,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.42,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.96,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.63,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >